The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis (Q34579232)

3 August 2017

1 reference

title

The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis (English)

1 reference

3 August 2017

0 references

Marcelo Kremenchutzky

series ordinal

1

1 reference

3 August 2017

Sarah Morrow

series ordinal

2

1 reference

3 August 2017

Carolina Rush

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Expert Opinion on Drug Safety

3 August 2017

1 reference

3 August 2017

6

1 reference

3 August 2017

3

1 reference

3 August 2017

279-288

1 reference

Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management

3 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Therapeutic role of beta-interferons in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Drug Insight: interferon treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Early treatment and dose optimisation BENEFIT and BEYOND.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Diagnosis and disease modifying treatments in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Disease-modifying therapy in multiple sclerosis: strategies for optimizing management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Multiple sclerosis: side effects of interferon beta therapy and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Interferons in relapsing remitting multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Interferon treatment may trigger primary headaches in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Liver injury associated with the beta-interferons for MS: a comparison between the three products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Thyroid autoimmunity and dysfunction associated with type I interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Cause of death in patients attending multiple sclerosis clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Psychiatric side effects of interferon-beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Cancer risk among patients with multiple sclerosis: a population-based register study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Meningioma growth and interferon beta-1b treated multiple sclerosis: coincidence or relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.3.279

21 January 2018

Identifiers

DOI

10.1517/14740338.6.3.279

1 reference

3 August 2017

1 reference